Advertisement
Mayo Clinic Proceedings Home

Selection of Antiepileptic Drugs: A Practical Approach

      The selection of antiepileptic drugs (AEDs) is increasingly more complex as new agents become available. We discuss an individualized approach to selection of an AED that is tailored to each patient's needs by considering the following six factors: effectiveness of the drug in controlling seizures, adverse effects profile, pharmacokinetic properties, special or unique patient situations, drug interactions, and cost of treatment. When these factors are considered, treatment complications and failure can be minimized by anticipating incompatibilities among drugs or between the drugs and the patient's condition. We emphasize the concept that the best AED therapy is dependent on optimal seizure control and absence of unacceptable side effects. In the current environment of medical practice, the cost of treatment has also become a mao jor concern. With rare exceptions, no single factor dictates the choice of an AED. In the long term, the most cost-effective treatment will be the one that provides the most therapeutic benefit with the fewest complications and maximal patient satisfaction.
      AEDs (antiepileptic drugs), GTCS (generalized tonic-clonic seizures), OCs (oral contraceptives)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hauser WA
        • Hesdorffer DC
        Epilepsy: Frequency, Causes and Consequences. Demos,, New York1990
        • Masland RL
        Commission for the control of epilepsy.
        Neurology. 1978; 28: 861-863
        • Steiner Tl
        • Yuen AW
        Comparison of lamotrigine and phenytoin monotherapy in newly diagnosed epilepsy [abstract].
        Epilepsia. 1994; 35: 31
        • Yuen AW
        Lamotrigine vs carba-mazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy [abstract].
        Epilepsia. 1994; 35 (and 106 investigators): 31
        • Anhut H
        • Ashman P
        • Feuerstein TJ
        • Sauermann W
        • Saunders M
        • Schmidt B
        • et al.
        Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study.
        Epilepsia. 1994; 35: 795-801
        • Andrews CO
        • Fischer JH
        Gabapentin: a new agent for the management of epilepsy.
        Ann Pharmacother. 1994; 28: 1188-1196
        • Sato S
        • White BG
        • Penry JK
        • Dreifuss FE
        • Sackellares JC
        • Kupferberg HJ
        Valproic acid versus ethosuximide in the treatment of absence seizures.
        Neurology. 1982; 32: 157-163
        • Penry JK
        • So EL
        Refractoriness of absence seizures and phenobarbital [abstract].
        Neurology. 1981; 31: 158
        • Snead III, OC
        • Hosey LC
        Exacerbation of seizures in children by carbamazepine.
        N Engl J Med. 1985; 313: 916-921
        • Lorentz de Haas AM
        • Kuilman M
        Ethosuximide (a-ethyl-a-methylsuccinimide) and grand mal.
        Epilepsia. 1964; 5: 90-96
        • Wilder BJ
        • Ramsay RE
        • Murphy JV
        • Karas BJ
        • Marquardt K
        • Hammond EJ
        Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures.
        Neurology. 1983; 33: 1474-1476
        • Schlumberger E
        • Chavez F
        • Palacios L
        • Rey E
        • Pajot N
        • Dulac O
        Lamotrigine in treatment of 120 children with epilepsy.
        Epilepsia. 1994; 35: 359-367
        • Strumia S
        • Hirsch E
        • Moszkowski J
        • Marescaux C
        Lamotrigine effect in typical absences [abstract].
        Epilepsia. 1994; 35: 118
        • Mikati MA
        • Holmes GL
        Temporal lobe epilepsy.
        in: Wyllie E The Treatment of Epilepsy: Principles and Practice. Lea & Febiger,, Philadelphia1993: 513-524
        • Mattson RH
        • Cramer JA
        • Collins JF
        • Smith DB
        • Delgado-Escueta AV
        • Browne TR
        • et al.
        Comparison of carba-mazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.
        N Engl J Med. 1985; 313: 145-151
        • Chadwick D
        • Turnbull DM
        The comparative efficacy of antiepileptic drugs for partial and tonic-clonic seizures.
        J Neurol Neurosurg Psychiatry. 1985; 48: 1073-1077
        • Callaghan N
        • Kenny RA
        • O'Neill B
        • Crowley M
        • Goggin T
        A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy.
        J Neurol Neurosurg Psychiatry. 1985; 48: 639-644
        • Turnbull DM
        • Rawlins MD
        • Weightman D
        • Chadwick DW
        A comparison of phenytoin and valproate in previously untreated adult epileptic patients.
        J Neurol Neurosurg Psychiatry. 1982; 45: 55-59
        • Mattson RH
        • Cramer JA
        • Collins JF
        • Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group
        A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults.
        N Engl J Med. 1992; 327: 765-771
        • Leiderman DB
        Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials.
        Epilepsia. 1994; 35: S74-S76
        • Yuen AW
        Lamotrigine: a review of antiepileptic efficacy.
        Epilepsia. 1994; 35: S33-S36
        • Leppik IE
        Felbamate.
        Epilepsia. 1995; 36: S66-S72
        • Mosewich RK
        • So EL
        A clinical approach to the classification of seizures and epileptic syndromes.
        Mayo Clin Proc. 1996; 71: 405-414
        • Mattson RH
        • Cramer JA
        Crossover from polytherapy to monotherapy in primary generalized epilepsy.
        Am J Med. 1988; 84: 23-28
        • Serratosa JM
        • Delgado-Escueta AV
        Generalized myoclonic seizures.
        in: Wyllie E The Treatment of Epilepsy: Principles and Practice. Lea & Febiger,, Philadelphia1993: 411-424
        • Serratosa JM
        • Delgado-Escueta AV
        Juvenile myoclonic epilepsy.
        in: Wyllie E The Treatment of Epilepsy: Principles and Practice. Lea & Febiger,, Philadelphia1993: 552-570
        • Eadie MJ
        • Tyrer JH
        Anticonvulsant Therapy: Pharmacological Basis and Practice. 3rd ed. Churchill Livingstone, Edinburgh1989
        • Janz D
        • Christe W
        Generalized epilepsies.
        in: Resor Jr, SR Kutt H The Medical Treatment of Epilepsy. Marcel Dekker,, New York1992: 145-162
        • Janz D
        Epilepsy with impulsive petit mal (juvenile myo-clonic epilepsy).
        Acta Neurol Scand. 1985; 72: 449-459
        • Genton P
        • Roger J
        The progressive myoclonus epilepsies.
        in: Wyllie E The Treatment of Epilepsy: Principles and Practice. Lea & Febiger,, Philadelphia1993: 571-583
        • Asconape J
        • Diedrich A
        • Della Badia J
        Gabapentin-associated myoclonus [abstract].
        Neurology. 1995; 45: A249-A250
        • Bachman DS
        Use of valproic acid in treatment of infantile spasms.
        Arch Neurol. 1982; 39: 49-52
        • Snead III, OC
        • Benton JW
        • Myers GJ
        ACTH and prednisone in childhood seizure disorders.
        Neurology. 1983; 33: 966-970
        • Chiron C
        • Dulac O
        • Beaumont D
        • Palacios L
        • Pajot N
        • Mumford J
        Therapeutic trial of vigabatrin in refractory infantile spasms.
        J Child Neurol. 1991; 6: S52-S59
        • Vies JS
        • van der Heyden AM
        • Ghijs A
        • Troost J
        Vigabatrin in the treatment of infantile spasms.
        Neuropediatrics. 1993; 24: 230-231
        • Richens A
        Safety of lamotrigine.
        Epilepsia. 1994; 35: S37-S40
        • Dreifuss FE
        • Langer DH
        • Moline KA
        • Maxwell IE
        VaJproic acid hepatic fatalities. II. US experience since 1984.
        Neurology. 1989; 39: 201-207
        • Hart RG
        • Easton JD
        Carbamazepine and hematological monitoring.
        Ann Neurol. 1982; 11: 309-312
        • Dreifuss FE
        • Santilli N
        • Langer DH
        • Sweeney KP
        • Moline KA
        • Menander KB
        Valproic acid hepatic fatalities: a retrospective review.
        Neurology. 1987; 37: 379-385
        • Vining EP
        • Mellitis ED
        • Dorsen MM
        • Cataldo MF
        • Quaskey SA
        • Spielberg SP
        • et al.
        Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid.
        Pediatrics. 1987; 80: 165-174
        • Schmidt D
        Connective tissue disorders induced by anti-epileptic drugs.
        in: Oxley J Janz D Meinardi H Chronic Toxicity of Antiepileptic Drugs. Raven Press,, New York1983: 115-124
        • Grisso JA
        • Kelsey JL
        • Strom BL
        • Chiu GY
        • Maislin G
        • O'Brien LA
        • et al.
        Risk factors for falls as a cause of hip fractures in women.
        N Engl J Med. 1991; 324: 1326-1331
        • Soelberg Sorenson P
        • Hammer M
        Effects of long-term carbamazepine treatment on water metabolism and plasma vasopressin concentration.
        Eur J Clin Pharmacol. 1984; 26: 719-722
        • Beermann B
        • Edhag O
        Depressive effects of carbamazepine on idioventricular rhythm in man.
        BMJ. 1978; 2: 171-172
        • Earnest MP
        • Marx JA
        • Drury LR
        Complications of intravenous phenytoin for acute treatment of seizures.
        JAMA. 1983; 249: 762-765
        • So EL
        • Penry JK
        Adverse effects of phenytoin on peripheral nerves and neuromuscular junctions.
        Epilepsia. 1981; 22: 467-473
        • Isojarvi Jl
        • Laatikainen TJ
        • Pakarinen AJ
        • Juntunen KT
        • Myllyla VV
        Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy.
        N Engl J Med. 1993; 329: 1383-1388
        • Painter MJ
        • Pippenger C
        • Wasterlain C
        • Barmada M
        • Pitlick W
        • Carter G
        • et al.
        Phenobarbital and phenytoin in neonatal seizures: metabolism and tissue distribution.
        Neurology. 1981; 31: 1107-1112
        • Terrence C
        • Alberts M
        Phenytoin dosage in ambulant epileptic patients.
        J Neurol Neurosurg Psychiatry. 1978; 41: 463-465
        • McLean MJ
        Clinical pharmacokinetics of gabapentin.
        Neurology. 1994; 44: S17-S22
        • Krauss GL
        • Simmons-O'Brien E
        • Campbell M
        Successful treatment of seizures and porphyria with gabapentin.
        Neurology. 1995; 45: 594-595
        • Hunt PA
        • Wu-Chen ML
        • Handal NJ
        • Chang CT
        • Gomez M
        • Howell TR
        • et al.
        Bone disease induced by anticonvulsant therapy and treatment with calcitriol (1,25-dihydroxyvitamin 03).
        Am J Dis Child. 1986; 140: 715-718
        • Brodie MJ
        • Forrest G
        • Rapeport WG
        Carbamazepine 10,11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants.
        Br J Clin Pharmacol. 1983; 16: 747-749
        • Levy RH
        • Moreland TA
        • Morselli PL
        • Guyot M
        • Brachet-Liermain A
        • Loiseau P
        Carbamazepine/valproic acid interaction in man and rhesus monkey.
        Epilepsia. 1984; 25: 338-345
        • Kondo T
        • Kaneko S
        • Otani K
        • Ishida M
        • Hirano T
        • Fukushima Y
        • et al.
        Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism.
        Epilepsia. 1992; 33: 172-177
        • Stephens JR
        • Levy RH
        Valproate hepatotoxicity syndrome: hypotheses of pathogenesis.
        Pharmaceutisch Weekblad [Sci Ed]. 1992; 14: 118-121
        • Kochen W
        • Schneider A
        • Ritz A
        Abnormal metabolism of valproic acid in fatal hepatic failure.
        Eur J Pediatr. 1983; 141: 30-35
        • So EL
        • Ruggles KH
        • Cascino GD
        • Ahmann PA
        • Weatherford KW
        Seizure exacerbation and status epilepticus related to carbamazepine-10,11-epoxide.
        Ann Neurol. 1994; 35: 743-746
        • Wilder BJ
        • Bruni J
        Seizure Disorders: Pharmacological Approach to Treatment. Raven Press,, New York1981: 35-39
        • Jonkman JH
        • Upton RA
        Pharmacokinetic drug interactions with theophylline.
        Clin Pharmacokinet. 1984; 9: 309-334
        • Wong DD
        • Longenecker RG
        • Liepman M
        • Baker S
        • LaVergne M
        Phenytoin-dexamethasone: a possible drug-drug interaction [letter].
        JAMA. 1985; 254: 2062-2063
        • Hansen JM
        • Siersbaek-Nielsen K
        • Skovsted L
        Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man.
        Clin Pharmacol Ther. 1971; 12: 539-543
        • Nappi JM
        Warfarin and phenytoin interaction [letter].
        Ann Intern Med. 1979; 90: 852
        • Panegyres PK
        • Rischbieth RH
        Fatal phenytoin warfarin interaction [letter].
        Postgrad Med J. 1991; 67: 98
        • Coulam CB
        • Annegers JF
        Do anticonvulsants reduce the efficacy of oral contraceptives?.
        Epilepsia. 1979; 20: 519-525
        • Crawford P
        • Chadwick D
        • Cleland P
        • Tjia J
        • Cowie A
        • Back DJ
        • et al.
        The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids.
        Contraception. 1986; 33: 23-29
        • Shenfield GM
        Oral contraceptives: are drug interactions of clinical significance?.
        Drug Saf. 1993; 9: 21-37
        • Wilder BJ
        • Willmore LJ
        • Bruni J
        • Villarreal HJ
        Valproic acid: interaction with other anticonvulsant drugs.
        Neurology. 1978; 28: 892-896
        • Rambeck B
        • Wolf P
        Lamotrigine clinical pharmacokinetics.
        Clin Pharmacokinet. 1993; 25: 433-443
        • Brennan RW
        • Dehejia H
        • Kutt H
        • Verebely K
        • McDowell F
        Diphenylhydantoin intoxication attendant to slow inactivation of isoniazid.
        Neurology. 1970; 20: 687-693
        • Kutt H
        Interactions between anticonvulsants and other commonly prescribed drugs.
        Epilepsia. 1984; 25: S118-S131
        • Darley J
        Interaction between phenytoin and fluoxetine.
        Seizure. 1994; 3: 151-152
        • Valsalan VC
        • Cooper GL
        Carbamazepine intoxication caused by interaction with isoniazid.
        BMJ. 1982; 285: 261-262
        • Kater RM
        • Roggin G
        • Tobon F
        • Zieve P
        • Iber FL
        Increased rate of clearance of drugs from the circulation of alcoholics.
        Am J Med Sci. 1969; 258: 35-39
        • Kutt H
        • Haynes J
        • Verebely K
        • McDowell F
        The effect of phenobarbital on plasma diphenylhydantoin level and metabolism in man and in rat liver microsomes.
        Neurology. 1969; 19: 611-616
        • Gunderson CH
        The impact of new pharmaceutical agents on the cost of neurologic care.
        Neurology. 1995; 45: 569-572